rating: +20+x

Item#: 7875
Containment Class:
Secondary Class:
Disruption Class:
Risk Class:

Special Containment Procedures:
All in vitro samples of SCP-7875 are to be stored in a ULT Freezer1 in Site-92's Pathology Wing. Testing with SCP-7875 must be approved by Dir. McIntyre, with Level-3 personnel or higher supervising said testing has been suspended until further notice. In the event of a mechanical failure of said storage units, mobile Scranton Reality Anchors (SRAs) are to be deployed to ensure the containment of all in vitro samples.

Any personnel found to be infected2 with SCP-7875 are to be immediately quarantined within a modified Negative Pressure Isolation Unit (NPIU)3. Under no circumstances are healthy Foundation personnel permitted close contact with SCP-7875-a instances. Any physical interactions with infected instances must be conducted via Remote-Piloted Medical Drones (RPMDs).

Should an instance of SCP-7875-a expire, or otherwise attempt to breach containment, attending personnel are to immediately enact the following procedure.


A space-filled 3D model of the proposed quaternary structure for SCP-7875-1

SCP-7875 denotes a previously unidentified, extremophilic strain of Acinetobacter baumannii. Found exclusively in Site-92's Medical Wing, SCP-7875 shares many similarities to other members of its species, primarily in regards to their nosocomial nature5 and general cellular anatomy. Where SCP-7875 differs from other strains is its expression of SCP-7875-16.

A 0.97 MDa protein complex, expression of SCP-7875-1 results in the absorption of ambient Hume levels in its immediate environment. While this typically results in mild spatial distortions in non-organic environments like medical equipment, when present in living organisms, the reduction of Hume levels gradually dematerializes the host's affected tissue7.

In addition to this ontokinetic manipulation, SCP-7875 has also displayed an anomalously high level of genetic plasticity. While the exact mechanism behind such plasticity is under investigation, current hypotheses link this genetic reparability to the heightened expression of RecA proteins8. It is further believed that SCP-7875-1 contributes to this anomalously rapid activity, converting excess ontokinetic energy from the absorbed Hume Fields into mechanical energy for these RecA proteins.

Due to this rapid rate of genetic alteration, treatment of SCP-7875 infections have become increasingly difficult. While the onset of symptoms in those infected progresses at a rate comparable to other A. baumannii strains, SCP-7875's reparability has rendered all available anti-biotic treatments nigh-ineffective. Presently, Adaptive Phage Therapy (APT) has proven to be the only viable means of counteracting said infections.

Should an SCP-7875-a instance be left untreated, or otherwise succumbs to their infection, SCP-7875 will completely dematerialize the infected subject. Upon reaching this stage, the remaining SCP-7875 colonies will proceed to restructure themselves into a biofilm, effectively laying dormant until a new subject has been infected.

For details surrounding the discovery of SCP-7875, see Addenda 7875-1 through -5.

Addendum 7875-1: Excerpt from Project Panacea Proposal

Dr. E. Aldrich, Dr. R. Carvalho, Dr. Y. Hasashi

Since the emergence of streptomycin resistant M. tuberculosis in the 1940's, humanity has remained in a persistent struggle against anti-microbial resistant (AMR) bacteria. Pathogens like S. aureus and the aforementioned M. tuberculosis, once thought to be treatable through the use of anti-biotics, re-emerged more potent than before. While the discoveries made during the so called "Golden Age of Anti-Biotics" kept many of these AMR bacteria at bay, human exploration and innovation could only stretch so far. This well-intentioned, but flawed effort resulted in many of the Multidrug-Resistant Pathogens (MDRPs) seen today, ravaging both public and Foundation-affiliated healthcare facilities alike.

Specifically in regards to the latter, Site-47's Logistics Division has reported a staggering ███ deaths across all Foundation Sites as a direct result of such infections in 2022 alone, up 175% from 2019's toll. While this value is ultimately a culmination of various AMR bacterial infections, one pathogen in particular that has resulted in upwards of 65% of such deaths is Acinetobacter baumannii.

An opportunistic, Gram-negative bacterium, A. baumannii has displayed an unnatural level of resistance to nearly all classes of available anti-biotics. While research has strongly affiliated this resistance to the expression of the RecA protein complex, efforts to effectively target this DNA repair complex have been futile. As a result, polymyxins are one of the few viable therapeutic avenues capable of halting the spread of A. baumannii infections. However, the limited supply of such anti-biotics can not nearly match the ever increasing demand, leaving many patients in dire need for new, innovative treatment options. This is in addition to the ever-increasing risk that A. baumannii will eventually develop resistance pathways to counteract polymyxin treatment.

While this would almost certainly spell doom for public healthcare facilities, pathological research conducted throughout Foundation facilities has already begun exploring promising alternatives to anti-biotic treatments. One of the most notable candidates, which this proposal will further explore, is an experimental therapy whose aim is to completely eradicate the presence of foreign pathogens in a host's body. Currently dubbed "Hume Therapy", this treatment utilizes an array of modified Scranton Reality Anchors to target the genetic sequence of a pathogen, in this case, A. baumannii, and counteract its Hume signature with an opposing field. This interaction between the two fields effectively results in the erasure of the targeted pathogen from baseline reality.

Materials & Methodology

Genomic Hume Targeting
Using early schematics of Dr. Scranton's eponymous Reality Anchors, Dr. Hasashi and her colleagues in the Department of Applied Ontokinetics were able to integrate a series of modifications into said SRA models. Such adjustments included the insertion of components like a MicroKant Scanner, and a Prokaryotic BLAST Database, amongst others which can be found in Figure 2c. By implementing these modifications, the newly dubbed Genomic Reality Anchors (GRAs) were able to effectively scan for and target genetic sequences inherently unique to the model organism in question.

Much like a matter-antimatter annihilation event, this targeting would induce a counter-field to negate the natural Hume signature of the genetic sequence in question, erasing it from baseline reality. By mapping out genomic regions vital to the pathogen's survival, the erasure of these sequences would induce a widespread apoptotic event throughout these foreign bodies, while leaving the host unharmed.

Model Organisms
The model organisms that were used in this study were provided by Site-107's Department of Microbiology. These organisms included the following; Acinetobacter baylyi (Variants 87, 105, 149, 289, 302, and 375), Escherichia coli variant 401, and Enterococcus faecalis variant 269. All organisms were handled and grown in accordance to the Foundation Regulatory Guidelines for Microorganism Experimentation. Also provided by Site-107 were 5 Mus musculus subjects for in vivo testing. As with the previously mentioned bacteria, all Mus musculus organisms were handled and cared for in accordance to the Foundation Ethical and Regulatory Guidelines for In Vivo Experimentation.


Objective Test Subject Result
Ensure the efficacy of Hume Therapy on single bacterium species A single Petri Dish of Acinetobacter Baylyi Complete ontokinetic annihilation of all present bacterial colonies
Ensure the accuracy of Hume Therapy in the presence of numerous bacterial species A multi-streaked Petri Dish consisting of A. baylyi9, E. coli, and E. faecalis Complete ontokinetic annihilation of A. baylyi. E. coli and E. faecalis colonies remained untouched.
Ensure the accuracy of Hume Therapy in the presence of related bacterial species A multi-streaked Petri Dish consisting of 6 variants of A. baylyi10 Complete ontokinetic annihilation of V149, with the other 5 variant colonies remaining unharmed
Observe the effects of Hume Therapy in an in vivo model Mus musculus infected with attenuated, pathogenic variant of A. baylyi Complete ontokinetic annihilation of A. baylyi. No detrimental effects observed in model organism

The following figure is a summary of all pre-clinical testing done using Hume Therapy on a variety of model organisms. Testing was primarily conducted by Dr. Riccardo Carvalho, under the direct supervision of Dr. Aldrich and Dr. Hasashi

Addendum 7875-3: Clinical Trials

Prior to testing, Site-92's Medical Wing was screened for A. baumannii induced infections, the results of which can be observed in the following figure.

Date: 26/06/2022
Attending: Dr. Riccardo Carvalho, Dr. Yelena Hasashi
Diagnosis: Urinary Tract Infection (UTI)
Treatment: Genomic Hume Therapy.
Results: Urinary analysis displayed negative test result. 053 experienced a full recovery approximately 36 hours post treatment.

Addendum 7875-4: Patient Zero Timeline

Despite the initial success of GHT in treating various A. baumannii borne infections, Patient-007 displayed an unusual reaction to their treatment. A timeline of their reaction can be found below, recorded by attending physician Dr. Riccardo Carvalho.

Date: 05/07/2022
Attending: Dr. Riccardo Carvalho
Observations: Patient 007 has displayed no adverse reaction to Genomic Hume Therapy. Their prior symptoms still remain, but could be linked to a lingering immune response. They will remain on a cephalosporin cocktail and fluid replacement until their vitals have stabilized. In the meanwhile, I've gone ahead and extracted a needle biopsy sample from the subject's pulmonary tissue to scan for any remaining bacterial colonies.



Unless otherwise stated, the content of this page is licensed under Creative Commons Attribution-ShareAlike 3.0 License